Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease ...

US biotech Aldeyra Therapeutics is making another attempt to gain marketing approval for its eye drop treatment reproxalap, a ...

Amidst global trade tensions, at least five companies from mainland China and Hong Kong are planning IPOs, dual listings, or ...

A phase 3 trial of Aldeyra Therapeutics’ dry eye disease prospect has hit its primary endpoint, preparing the biotech to seek approval for a candidate the FDA has rejected twice in recent years.

Channel Therapeutics reports CT2000 reduced eye pain in preclinical trials, with plans to enter human testing for acute and ...

At least five companies from mainland China or Hong Kong are planning IPOs, dual listings, or share placements in Singapore in the next 12 to 18 months, four sources said, as Chinese firms look to ...

Swiss pharma giant Roche is investing $280 million to build a new biopharma manufacturing facility in Shanghai, as it doubles ...

At least five Chinese and HK firms eye listings on SGX. Read more at straitstimes.com. Read more at straitstimes.com.

IN BRIEFUS Patent Office granted Active Biotech's patent application for laquinimod in eye disorders (January 28)Active Biotech announced that the first patient was enrolled in the European ...

With growing uncertainty in US financial markets and research funding, Chinese companies are swooping in to present ...

Neurotech in May won FDA approval for its MacTel therapy. Former J&J CEO named lead director at RI-based biotech firm Feds fund biotech workforce program in Rhode Island Feds fund biotech ...